| 1.66 0.07 (4.4%) | 08-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2  |
1-year : | 2.34 |
| Resists | First : | 1.72 |
Second : | 2 |
| Pivot price | 1.6 |
|||
| Supports | First : | 1.56 |
Second : | 1.47 |
| MAs | MA(5) : | 1.61 |
MA(20) : | 1.6 |
| MA(100) : | 2.16 |
MA(250) : | 3.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57.5 |
D(3) : | 46.4 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 6.38 | Low : | 1.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMNN ] has closed above the upper band by 0.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 77.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.7 - 1.71 | 1.71 - 1.72 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.65 - 1.66 | 1.66 - 1.67 |
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Fri, 21 Aug 2026
IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial - Smartkarma
Mon, 17 Aug 2026
Imunon (IMNN) pays executive chair with 7,147 shares - Stock Titan
Mon, 17 Aug 2026
Imunon (IMNN) counsel gets stock in lieu of pay, then sells 2,449 shares - Stock Titan
Mon, 17 Aug 2026
Imunon (IMNN) CEO takes 6,615 shares instead of cash pay - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 5.6 (%) |
| Shares Short | 150 (K) |
| Shares Short P.Month | 51 (K) |
| EPS | -2.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -78 % |
| Return on Equity (ttm) | -429.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.08 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | 5 |
| Price to Book value | 4.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|